Long-term outcomes by lobular vs ductal histology in 4 National Surgical Adjuvant Breast and Bowel Project adjuvant breast cancer trials
JNCI: Journal of the National Cancer Institute · 2025
DOI: 10.1093/jnci/djae188 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Julia Foldi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Chemotherapy, Adjuvant. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, Breast Cancer Research Foundation.
Abstract (Originalsprache)
We evaluated differences in long-term outcomes of invasive lobular carcinoma vs breast cancers of no special type treated with anthracycline-based adjuvant chemotherapy using 4 National Surgical Adjuvant Breast and Bowel Project randomized phase III trials (B-22, B-25, B-28, and B-30). Our cohort included 11 251 patients with no special type and 1231 with invasive lobular carcinoma. Patients with invasive lobular carcinoma were older, had larger and more frequently estrogen receptor–positive tumors, and more positive lymph nodes. During early follow-up (0-5 years), patients with invasive lobular carcinoma had fewer recurrences (hazard ratio [HR] = 0.797, 95% confidence interval [CI] = 0.685 to 0.929) and deaths (HR = 0.756, 95% CI = 0.623 to 0.917). After 5 years, patients with invasive lobular carcinoma had more recurrences (HR = 1.30, 95% CI = 1.085 to 1.558) and deaths (HR = 1.044, 95% CI = 0.898 to 1.214). Conditional probability analysis showed statistically significant interactions between time-period and histologic type for recurrences (P < .001) and deaths (P < .001). Patients with invasive lobular carcinoma have elevated risk of late recurrence and death compared with patients with no special type cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
- Women's Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC), Pittsburgh, PA, USA.
- Department of Biostatistics, University of Pittsburgh School of Public Health, Pittsburgh, PA, USA.
- UPMC HCC and NSABP Foundation, Inc, Pittsburgh, PA, USA.
- Magee-Womens Research Institute, Pittsburgh, PA, USA.
- Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.
ORCID-Profile: Julia Foldi, Neil Carleton, Stewart J Anderson, Priya Rastogi, Adrian Lee, Marija Balic, Charles E Geyer, Steffi Oesterreich, Norman Wolmark
Förderung
- NCI NIH HHS
- NIH HHS
- Breast Cancer Research Foundation
- Conquer Cancer Foundation
- AstraZeneca
- National Institutes of Health
- NCI
Zitieren
APA
Foldi, J., Carleton, N., Anderson, S. J., Rastogi, P., Lee, A., Balic, M., Geyer, C. E., Oesterreich, S., & Wolmark, N. (2025). Long-term outcomes by lobular vs ductal histology in 4 National Surgical Adjuvant Breast and Bowel Project adjuvant breast cancer trials. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae188
Vancouver
Foldi J, Carleton N, Anderson SJ, Rastogi P, Lee A, Balic M, et al. Long-term outcomes by lobular vs ductal histology in 4 National Surgical Adjuvant Breast and Bowel Project adjuvant breast cancer trials. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djae188
BibTeX
@article{Foldi2025,
author = {Foldi, Julia and Carleton, Neil and Anderson, Stewart J and Rastogi, Priya and Lee, Adrian and Balic, Marija and Geyer, Charles E and Oesterreich, Steffi and Wolmark, Norman},
title = {Long-term outcomes by lobular vs ductal histology in 4 National Surgical Adjuvant Breast and Bowel Project adjuvant breast cancer trials},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
doi = {10.1093/jnci/djae188}
}
EUVIMED